Gene–environment interactions in development and disease

Wiley Interdisciplinary Reviews: Developmental Biology

Volumn 6, Issue 1, 2017, Pages

  Lovely, C ^a   Rampersad, Mindy ^a   Fernandes, Yohaan ^a   Eberhart, Johann ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; THALIDOMIDE;

CANCER RISK; DEVELOPMENTAL GENE; DRUG ALCOHOL INTERACTION; EMBRYO; ENVIRONMENTAL FACTOR; FACIES; FETAL ALCOHOL SYNDROME; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HIRSCHSPRUNG DISEASE; HUMAN; INTELLIGENCE QUOTIENT; MICROGNATHIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; DEVELOPMENTAL BIOLOGY; DISEASES; GENE EXPRESSION REGULATION; GENETICS;

DEVELOPMENTAL BIOLOGY; DISEASE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE-ENVIRONMENT INTERACTION; HUMANS;

EID: 84992602848     PISSN: 17597684     EISSN: 17597692     Source Type: Journal    
DOI: 10.1002/wdev.247     Document Type: Review

References (123)

1. The following recent reviews will be of interest to readers wishing to understand our current knowledge of the roles of gene–environment interactions in complex psychological disorders.
2. Mandy W, Lai M-C. Annual research review: the role of the environment in the developmental psychopathology of autism spectrum condition. J Child Psychol Psychiatry 2016, 57:271–292.
3. Ayhan Y, McFarland R, Pletnikov MV. Animal models of gene-environment interaction in schizophrenia: a dimensional perspective. Prog Neurobiol 2016, 136:1–27.
4. Klengel T, Binder EB. Epigenetics of stress-related psychiatric disorders and gene × environment interactions. Neuron 2015, 86:1343–1357.
5. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006, 7:583–590.
6. Woolf LI. The heterozygote advantage in phenylketonuria. Am J Hum Genet 1986, 38:773–775.
7. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992, 41:1–7.
8. Marean A, Graf A, Zhang Y, Niswander L. Folic acid supplementation can adversely affect murine neural tube closure and embryonic survival. Hum Mol Genet 2011, 20:3678–3683.
9. Mikael LG, Deng L, Paul L, Selhub J, Rozen R. Moderately high intake of folic acid has a negative impact on mouse embryonic development. Birth Defects Res A Clin Mol Teratol 2013, 97:47–52.
10. Pickell L, Brown K, Li D, Wang XL, Deng L, Wu Q, Selhub J, Luo L, Jerome-Majewska L, Rozen R. High intake of folic acid disrupts embryonic development in mice. Birth Defects Res A Clin Mol Teratol 2011, 91:8–19.
11. Wu S, Powers S, Zhu W, Hannun YA. Substantial contribution of extrinsic risk factors to cancer development. Nature 2016, 529:43–47.
12. Landrigan PJ, De Garbino JP, Newman B. Framing the future in light of the past: living in a chemical world. Ann N Y Acad Sci 2006, 1076:657–659.
13. Aus der Beek T, Weber FA, Bergmann A, Hickmann S, Ebert I, Hein A, Kuster A. Pharmaceuticals in the environment—global occurrences and perspectives. Environ Toxicol Chem 2016, 35:823–835.
14. Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays 2009, 31:1327–1336.
15. Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 2011, 68:1569–1579.
16. Siamwala JH, Veeriah V, Priya MK, Rajendran S, Saran U, Sinha S, Nagarajan S, Pradeep T, Chatterjee S. Nitric oxide rescues thalidomide mediated teratogenicity. Sci Rep 2012, 2:679.
17. Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011, 122:1–6.
18. Zhou S, Wang F, Hsieh TC, Wu JM, Wu E. Thalidomide—a notorious sedative to a wonder anticancer drug. Curr Med Chem 2013, 20:4102–4108.
19. Schill EM, Lake JI, Tusheva OA, Nagy N, Bery SK, Foster L, Avetisyan M, Johnson SL, Stenson WF, Goldstein AM, et al. Ibuprofen slows migration and inhibits bowel colonization by enteric nervous system precursors in zebrafish, chick and mouse. Dev Biol 2016, 409:473–488.
20. Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, Pelet A, Arnold S, Miao X, Griseri P, et al. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet 2008, 45:1–14.
21. Sanders T, Liu Y, Buchner V, Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health 2009, 24:15–45.
22. Ordemann JM, Austin RN. Lead neurotoxicity: exploring the potential impact of lead substitution in zinc-finger proteins on mental health. Metallomics 2016, 8:579–588.
23. Grandjean P, Herz KT. Trace elements as paradigms of developmental neurotoxicants: lead, methylmercury and arsenic. J Trace Elem Med Biol 2015, 31:130–134.
24. Nathoo N, Chetty R, van Dellen JR, Barnett GH. Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E. Mol Pathol 2003, 56:132–136.
25. Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect 2002, 110:501–505.
26. Edwards GN. Two cases of poisoning by mercuric methide. Saint Bartholomew's Hosp Rep 1865, 1:141–150.
27. Harada M. Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology 1978, 18:285–288.
28. Ceccatelli S, Bose R, Edoff K, Onishchenko N, Spulber S. Long-lasting neurotoxic effects of exposure to methylmercury during development. J Intern Med 2013, 273:490–497.
29. Ng S, Lin CC, Hwang YH, Hsieh WS, Liao HF, Chen PC. Mercury, APOE, and children's neurodevelopment. Neurotoxicology 2013, 37:85–92.
30. Ng S, Lin CC, Jeng SF, Hwang YH, Hsieh WS, Chen PC. Mercury, APOE, and child behavior. Chemosphere 2015, 120:123–130.
31. Llop S, Engstrom K, Ballester F, Franforte E, Alhamdow A, Pisa F, Tratnik JS, Mazej D, Murcia M, Rebagliato M, et al. Polymorphisms in ABC transporter genes and concentrations of mercury in newborns—evidence from two Mediterranean birth cohorts. PLoS One 2014, 9:e97172.
32. Lee BE, Hong YC, Park H, Ha M, Koo BS, Chang N, Roh YM, Kim BN, Kim YJ, Kim BM, et al. Interaction between GSTM1/GSTT1 polymorphism and blood mercury on birth weight. Environ Health Perspect 2010, 118:437–443.
33. Chung KC, Kowalski CP, Kim HM, Buchman SR. Maternal cigarette smoking during pregnancy and the risk of having a child with cleft lip/palate. Plast Reconstr Surg 2000, 105:485–491.
34. Shi M, Christensen K, Weinberg CR, Romitti P, Bathum L, Lozada A, Morris RW, Lovett M, Murray JC. Orofacial cleft risk is increased with maternal smoking and specific detoxification-gene variants. Am J Hum Genet 2007, 80:76–90.
35. Jugessur A, Wilcox AJ, Murray JC, Gjessing HK, Nguyen TT, Nilsen RM, Lie RT. Assessing the impact of nicotine dependence genes on the risk of facial clefts: an example of the use of national registry and biobank data. Nor Epidemiol 2012, 21:241–250.
36. Machado RA, Moreira HS, de Aquino SN, Martelli-Junior H, de Almeida Reis SR, Persuhn DC, Wu T, Yuan Y, Coletta RD. Interactions between RAD51 rs1801321 and maternal cigarette smoking as risk factor for nonsyndromic cleft lip with or without cleft palate. Am J Med Genet A 2016, 170:536–539.
37. Romitti PA, Lidral AC, Munger RG, Daack-Hirsch S, Burns TL, Murray JC. Candidate genes for nonsyndromic cleft lip and palate and maternal cigarette smoking and alcohol consumption: evaluation of genotype-environment interactions from a population-based case-control study of orofacial clefts. Teratology 1999, 59:39–50.
38. Etheredge AJ, Christensen K, Del Junco D, Murray JC, Mitchell LE. Evaluation of two methods for assessing gene-environment interactions using data from the Danish case-control study of facial clefts. Birth Defects Res A Clin Mol Teratol 2005, 73:541–546.
39. Mitchell LE, Murray JC, O'Brien S, Christensen K. Evaluation of two putative susceptibility loci for oral clefts in the Danish population. Am J Epidemiol 2001, 153:1007–1015.
40. Esposito ER, Horn KH, Greene RM, Pisano MM. An animal model of cigarette smoke-induced in utero growth retardation. Toxicology 2008, 246:193–202.
41. Stockard CR. The influence of alcohol and other anaesthetics on embryonic development. Am J Anat 1910, 10:369–392.
42. Lemoine P, Harousseau H, Borteyru J-P, Menuet J-C. Les Enfants de parents alcooliques: anomalies observees a propos de 127 cas. Ouest Medical 1968, 21:476–482.
43. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973, 302:999–1001.
44. Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum disorders: an overview. Neuropsychol Rev 2011, 21:73–80.
45. Munger RG, Romitti PA, Daack-Hirsch S, Burns TL, Murray JC, Hanson J. Maternal alcohol use and risk of orofacial cleft birth defects. Teratology 1996, 54:27–33.
46. Nunez CC, Roussotte F, Sowell ER. Focus on: structural and functional brain abnormalities in fetal alcohol spectrum disorders. Alcohol Res Health 2011, 34:121–131.
47. Kodituwakku PW. Defining the behavioral phenotype in children with fetal alcohol spectrum disorders: a review. Neurosci Biobehav Rev 2007, 31:192–201.
48. Streissguth AP, Aase JM, Clarren SK, Randels SP, LaDue RA, Smith DF. Fetal alcohol syndrome in adolescents and adults. JAMA 1991, 265:1961–1967.
49. Roebuck TM, Mattson SN, Riley EP. Behavioral and psychosocial profiles of alcohol-exposed children. Alcohol Clin Exp Res 1999, 23:1070–1076.
50. Kelly SJ, Day N, Streissguth AP. Effects of prenatal alcohol exposure on social behavior in humans and other species. Neurotoxicol Teratol 2000, 22:143–149.
51. Kully-Martens K, Denys K, Treit S, Tamana S, Rasmussen C. A review of social skills deficits in individuals with fetal alcohol spectrum disorders and prenatal alcohol exposure: profiles, mechanisms, and interventions. Alcohol Clin Exp Res 2012, 36:568–576.
52. Flak AL, Su S, Bertrand J, Denny CH, Kesmodel US, Cogswell ME. The association of mild, moderate, and binge prenatal alcohol exposure and child neuropsychological outcomes: a meta-analysis. Alcohol Clin Exp Res 2014, 38:214–226.
53. Ethen MK, Ramadhani TA, Scheuerle AE, Canfield MA, Wyszynski DF, Druschel CM, Romitti PA, National Birth Defects Prevention Study. Alcohol consumption by women before and during pregnancy. Matern Child Health J 2009, 13:274–285.
54. Sampson PD, Streissguth AP, Bookstein FL, Little RE, Clarren SK, Dehaene P, Hanson JW, Graham JM Jr. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology 1997, 56:317–326.
55. May PA, Gossage JP, Kalberg WO, Robinson LK, Buckley D, Manning M, Hoyme HE. Prevalence and epidemiologic characteristics of FASD from various research methods with an emphasis on recent in-school studies. Dev Disabil Res Rev 2009, 15:176–192.
56. Rojmahamongkol P, Cheema-Hasan A, Weitzman C. Do pediatricians recognize fetal alcohol spectrum disorders in children with developmental and behavioral problems? J Dev Behav Pediatr 2015, 36:197–202.
57. Schneider ML, Moore CF, Adkins MM. The effects of prenatal alcohol exposure on behavior: rodent and primate studies. Neuropsychol Rev 2011, 21:186–203.
58. Kelly SJ, Goodlett CR, Hannigan JH. Animal models of fetal alcohol spectrum disorders: impact of the social environment. Dev Disabil Res Rev 2009, 15:200–208.
59. Murawski NJ, Moore EM, Thomas JD, Riley EP. Advances in diagnosis and treatment of fetal alcohol spectrum disorders: from animal models to human studies. Alcohol Res 2015, 37:97–108.
60. Sulik KK. Genesis of alcohol-induced craniofacial dysmorphism. Exp Biol Med (Maywood) 2005, 230:366–375.
61. Ponnappa BC, Rubin E. Modeling alcohol's effects on organs in animal models. Alcohol Res Health 2000, 24:93–104.
62. Becker HC, Diaz-Granados JL, Randall CL. Teratogenic actions of ethanol in the mouse: a minireview. Pharmacol Biochem Behav 1996, 55:501–513.
63. Kiecker C. The chick embryo as a model for the effects of prenatal exposure to alcohol on craniofacial development. Dev Biol 2016, 415:314–325.
64. Gerlai R. Fish in behavior research: unique tools with a great promise!. J Neurosci Methods 2014, 234:54–58.
65. Cudd TA. Animal model systems for the study of alcohol teratology. Exp Biol Med (Maywood) 2005, 230:389–393.
66. Williams JF, Smith VC, Committee on Substance Abuse. Fetal alcohol spectrum disorders. Pediatrics 2015, 136:e1395–e1406.
67. Streissguth AP, Dehaene P. Fetal alcohol syndrome in twins of alcoholic mothers: concordance of diagnosis and IQ. Am J Med Genet 1993, 47:857–861.
68. Eberhart JK, Parnell SE. The genetics of fetal alcohol spectrum disorders (FASD). Alcohol Clin Exp Res 2016, 40:1154–1165.
69. Cohen MM Jr, Shiota K. Teratogenesis of holoprosencephaly. Am J Med Genet 2002, 109:1–15.
70. Solomon BD, Mercier S, Velez JI, Pineda-Alvarez DE, Wyllie A, Zhou N, Dubourg C, David V, Odent S, Roessler E, et al. Analysis of genotype-phenotype correlations in human holoprosencephaly. Am J Med Genet C Semin Med Genet 2010, 154C:133–141.
71. Hong M, Krauss RS. Cdon mutation and fetal ethanol exposure synergize to produce midline signaling defects and holoprosencephaly spectrum disorders in mice. PLoS Genet 2012, 8:e1002999.
72. Kietzman HW, Everson JL, Sulik KK, Lipinski RJ. The teratogenic effects of prenatal ethanol exposure are exacerbated by Sonic Hedgehog or GLI2 haploinsufficiency in the mouse. PLoS One 2014, 9:e89448.
73. Zhang C, Ojiaku P, Cole GJ. Forebrain and hindbrain development in zebrafish is sensitive to ethanol exposure involving agrin, Fgf, and sonic hedgehog function. Birth Defects Res A Clin Mol Teratol 2013, 97:8–27.
74. Zhang C, Turton QM, Mackinnon S, Sulik KK, Cole GJ. Agrin function associated with ocular development is a target of ethanol exposure in embryonic zebrafish. Birth Defects Res A Clin Mol Teratol 2011, 91:129–141.
75. Li YX, Yang HT, Zdanowicz M, Sicklick JK, Qi Y, Camp TJ, Diehl AM. Fetal alcohol exposure impairs Hedgehog cholesterol modification and signaling. Lab Invest 2007, 87:231–240.
76. Dunty WC Jr, Chen SY, Zucker RM, Dehart DB, Sulik KK. Selective vulnerability of embryonic cell populations to ethanol-induced apoptosis: implications for alcohol-related birth defects and neurodevelopmental disorder. Alcohol Clin Exp Res 2001, 25:1523–1535.
77. Duester G. A hypothetical mechanism for fetal alcohol syndrome involving ethanol inhibition of retinoic acid synthesis at the alcohol dehydrogenase step. Alcohol Clin Exp Res 1991, 15:568–572.
78. Pullarkat RK. Hypothesis: prenatal ethanol-induced birth defects and retinoic acid. Alcohol Clin Exp Res 1991, 15:565–567.
79. Napoli JL. Effects of ethanol on physiological retinoic acid levels. IUBMB Life 2011, 63:701–706.
80. Zhang C, Anderson A, Cole GJ. Analysis of crosstalk between retinoic acid and sonic hedgehog pathways following ethanol exposure in embryonic zebrafish. Birth Defects Res A Clin Mol Teratol 2015, 103:1046–1057.
81. Kashyap B, Frey RA, Stenkamp DL. Ethanol-induced microphthalmia is not mediated by changes in retinoic acid or sonic hedgehog signaling during retinal neurogenesis. Alcohol Clin Exp Res 2011, 35:1644–1661.
82. Jacobson SW, Carr LG, Croxford J, Sokol RJ, Li TK, Jacobson JL. Protective effects of the alcohol dehydrogenase-ADH1B allele in children exposed to alcohol during pregnancy. J Pediatr 2006, 148:30–37.
83. Viljoen DL, Carr LG, Foroud TM, Brooke L, Ramsay M, Li TK. Alcohol dehydrogenase-2*2 allele is associated with decreased prevalence of fetal alcohol syndrome in the mixed-ancestry population of the Western Cape Province, South Africa. Alcohol Clin Exp Res 2001, 25:1719–1722.
84. Warren KR, Li TK. Genetic polymorphisms: impact on the risk of fetal alcohol spectrum disorders. Birth Defects Res A Clin Mol Teratol 2005, 73:195–203.
85. Das UG, Cronk CE, Martier SS, Simpson PM, McCarver DG. Alcohol dehydrogenase 2*3 affects alterations in offspring facial morphology associated with maternal ethanol intake in pregnancy. Alcohol Clin Exp Res 2004, 28:1598–1606.
86. McCarver DG, Thomasson HR, Martier SS, Sokol RJ, Li T. Alcohol dehydrogenase-2*3 allele protects against alcohol-related birth defects among African Americans. J Pharmacol Exp Ther 1997, 283:1095–1101.
87. Boyles AL, DeRoo LA, Lie RT, Taylor JA, Jugessur A, Murray JC, Wilcox AJ. Maternal alcohol consumption, alcohol metabolism genes, and the risk of oral clefts: a population-based case-control study in Norway, 1996–2001. Am J Epidemiol 2010, 172:924–931.
88. Brocardo PS, Gil-Mohapel J, Christie BR. The role of oxidative stress in fetal alcohol spectrum disorders. Brain Res Rev 2011, 67:209–225.
89. Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci 2007, 81:177–187.
90. Hernandez JA, Lopez-Sanchez RC, Rendon-Ramirez A. Lipids and oxidative stress associated with ethanol-induced neurological damage. Oxid Med Cell Longev 2016, 2016:1543809.
91. Wentzel P, Eriksson UJ. Ethanol-induced fetal dysmorphogenesis in the mouse is diminished by high antioxidative capacity of the mother. Toxicol Sci 2006, 92:416–422.
92. Chernoff GF. The fetal alcohol syndrome in mice: maternal variables. Teratology 1980, 22:71–75.
93. Gilliam DM, Irtenkauf KT. Maternal genetic effects on ethanol teratogenesis and dominance of relative embryonic resistance to malformations. Alcohol Clin Exp Res 1990, 14:539–545.
94. Langevin F, Crossan GP, Rosado IV, Arends MJ, Patel KJ. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011, 475:53–58.
95. Bonthius DJ, Tzouras G, Karacay B, Mahoney J, Hutton A, McKim R, Pantazis NJ. Deficiency of neuronal nitric oxide synthase (nNOS) worsens alcohol-induced microencephaly and neuronal loss in developing mice. Brain Res Dev Brain Res 2002, 138:45–59.
96. Bonthius DJ Jr, Winters Z, Karacay B, Bousquet SL, Bonthius DJ. Importance of genetics in fetal alcohol effects: null mutation of the nNOS gene worsens alcohol-induced cerebellar neuronal losses and behavioral deficits. Neurotoxicology 2015, 46:60–72.
97. Karacay B, Mahoney J, Plume J, Bonthius DJ. Genetic absence of nNOS worsens fetal alcohol effects in mice. II: microencephaly and neuronal losses. Alcohol Clin Exp Res 2015, 39:221–231.
98. McCarthy N, Wetherill L, Lovely CB, Swartz ME, Foroud TM, Eberhart JK. Pdgfra protects against ethanol-induced craniofacial defects in a zebrafish model of FASD. Development 2013, 140:3254–3265.
99. Eberhart JK, He X, Swartz ME, Yan YL, Song H, Boling TC, Kunerth AK, Walker MB, Kimmel CB, Postlethwait JH. MicroRNA Mirn140 modulates Pdgf signaling during palatogenesis. Nat Genet 2008, 40:290–298.
100. Soriano P. The PDGF α receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997, 124:2691–2700.
101. Tallquist MD, Soriano P. Cell autonomous requirement for PDGFRα in populations of cranial and cardiac neural crest cells. Development 2003, 130:507–518.
102. Rattanasopha S, Tongkobpetch S, Srichomthong C, Siriwan P, Suphapeetiporn K, Shotelersuk V. PDGFRa mutations in humans with isolated cleft palate. Eur J Hum Genet 2012, 20:1058–1062.
103. Klinghoffer RA, Hamilton TG, Hoch R, Soriano P. An allelic series at the PDGFαR locus indicates unequal contributions of distinct signaling pathways during development. Dev Cell 2002, 2:103–113.
104. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 2015, 25:545–555.
105. Swartz ME, Wells MB, Griffin M, McCarthy N, Lovely CB, McGurk P, Rozacky J, Eberhart JK. A screen of zebrafish mutants identifies ethanol-sensitive genetic loci. Alcohol Clin Exp Res 2014, 38:694–703.
106. Beaty TH, Ruczinski I, Murray JC, Marazita ML, Munger RG, Hetmanski JB, Murray T, Redett RJ, Fallin MD, Liang KY, et al. Evidence for gene-environment interaction in a genome wide study of nonsyndromic cleft palate. Genet Epidemiol 2011, 35:469–478.
107. Costa LG, Guizzetti M, Burry M, Oberdoerster J. Developmental neurotoxicity: do similar phenotypes indicate a common mode of action? A comparison of fetal alcohol syndrome, toluene embryopathy and maternal phenylketonuria. Toxicol Lett 2002, 127:197–205.
108. Toutant C, Lippmann S. Fetal solvents syndrome. Lancet 1979, 1:1356.
109. Wilkins-Haug L. Teratogen update: toluene. Teratology 1997, 55:145–151.
110. Pearson MA, Hoyme HE, Seaver LH, Rimsza ME. Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome. Pediatrics 1994, 93:211–215.
111. Darling KW, Ackerman SL, Hiatt RH, Lee SS, Shim JK. Enacting the molecular imperative: how gene-environment interaction research links bodies and environments in the post-genomic age. Soc Sci Med 2016, 155:51–60.
112. Chen L, Zhou S. “CRASH”ing with the worm: insights into L1CAM functions and mechanisms. Dev Dyn 2010, 239:1490–1501.
113. Arevalo E, Shanmugasundararaj S, Wilkemeyer MF, Dou X, Chen S, Charness ME, Miller KW. An alcohol binding site on the neural cell adhesion molecule L1. Proc Natl Acad Sci USA 2008, 105:371–375.
114. Dou X, Wilkemeyer MF, Menkari CE, Parnell SE, Sulik KK, Charness ME. Mitogen-activated protein kinase modulates ethanol inhibition of cell adhesion mediated by the L1 neural cell adhesion molecule. Proc Natl Acad Sci USA 2013, 110:5683–5688.
115. Balaraman S, Tingling JD, Tsai PC, Miranda RC. Dysregulation of microRNA expression and function contributes to the etiology of fetal alcohol spectrum disorders. Alcohol Res 2013, 35:18–24.
116. Mead EA, Sarkar DK. Fetal alcohol spectrum disorders and their transmission through genetic and epigenetic mechanisms. Front Genet 2014, 5:154.
117. Sen A, Cingolani P, Senut MC, Land S, Mercado-Garcia A, Tellez-Rojo MM, Baccarelli AA, Wright RO, Ruden DM. Lead exposure induces changes in 5-hydroxymethylcytosine clusters in CpG islands in human embryonic stem cells and umbilical cord blood. Epigenetics 2015, 10:607–621.
118. Mora-Zamorano FX, Klingler R, Murphy CA, Basu N, Head J, Carvan MJ III. Parental whole life cycle exposure to dietary methylmercury in zebrafish (Danio rerio) affects the behavior of offspring. Environ Sci Technol 2016, 50:4808–4816.
119. Xu X, Weber D, Martin A, Lone D. Trans-generational transmission of neurobehavioral impairments produced by developmental methylmercury exposure in zebrafish (Danio rerio). Neurotoxicol Teratol 2016, 53:19–23.
120. Baker TR, Peterson RE, Heideman W. Using zebrafish as a model system for studying the transgenerational effects of dioxin. Toxicol Sci 2014, 138:403–411.
121. Lombo M, Fernandez-Diez C, Gonzalez-Rojo S, Navarro C, Robles V, Herraez MP. Transgenerational inheritance of heart disorders caused by paternal bisphenol A exposure. Environ Pollut 2015, 206:667–678.
122. Volkova K, Reyhanian Caspillo N, Porseryd T, Hallgren S, Dinnetz P, Olsen H, Porsch Hallstrom I. Transgenerational effects of 17α-ethinyl estradiol on anxiety behavior in the guppy, Poecilia reticulata. Gen Comp Endocrinol 2015, 223:66–72.
123. Vignet C, Joassard L, Lyphout L, Guionnet T, Goubeau M, Le Menach K, Brion F, Kah O, Chung BC, Budzinski H, et al. Exposures of zebrafish through diet to three environmentally relevant mixtures of PAHs produce behavioral disruptions in unexposed F1 and F2 descendant. Environ Sci Pollut Res Int 2015, 22:16371–16383.